This is a Phase 1 safety and feasibility trial in a neurodegenerative disease population with no results yet posted; it is designed to generate early evidence on tolerability and enrollment, not to establish efficacy.
Reported
Planned sample size40
Study phasePhase 1
Primary outcome: adverse event ra…Proportion of participants with an AE up to…